

Disclosure of Value Transfers

Methodological Note

Country	Lithuania, Latvia, Estonia
Entity Name	Fresenius Kabi Baltics UAB
Legal Basis for Disclosure	<p>In general:</p> <ul style="list-style-type: none"> - Medicines for Europe Code of Conduct 2020, published February 2021 <p>Locally:</p> <ul style="list-style-type: none"> - Lithuania: Code of Ethics for Pharmaceutical Marketing. 2020 edition. Adopted by IFPA on 18/06/2020, VGA on 25/06/2020. Order of the Ministry of Health no. V-1537, 23/06/2020; - Estonia: Medicinal Products Act. 2005 edition. Clause 83. General requirements for advertising of medicinal products; - Latvia: Cabinet rules nr. 378, adopted on 17/05/2011, updated 09/09/2021.
Reporting Period	2022
Currency of disclosed values	<p>All values are disclosed in</p> <p><input checked="" type="checkbox"/> EUR</p> <p><input type="checkbox"/> [local currency, if required]</p>
Scope of disclosure	The disclosure covers all interactions with HCPs, HCOs and Patient Organizations. Medicines are related to all prescription-only medicinal products (generic, original or biosimilar). Interactions related to medical devices or enteral nutrition products are not disclosed.
Value identification and Recognition	All values disclosed are based on value transfers actually made to the respective category that such value transfer has been made to a specific recipient as booked in the respective reporting period (value of transfer for educational support is disclosed based on the reporting period of the event/congress).
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
Data disclosed for	<p>All values are disclosed for</p> <p><input type="checkbox"/> Recipients which have been engaged by entity</p> <p><input checked="" type="checkbox"/> Recipients which have their residence in the country (e.g. EFPIA and Medicines for Europe)</p>

Disclosure of Value Transfers

VAT and other taxes	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction, except for Company Organised Meetings/Site Visits, which are disclosed VAT excluded.
Disclosure location:	<ul style="list-style-type: none"> - Lithuania, Estonia (MfE disclosure): https://www.fresenius-kabi.com/company/transparency-initiative - Lithuania (State Agency of Medicines): https://www.vvkt.lt/index.php?3523782702 - Latvia (State Agency of Medicines): https://www.vi.gov.lv/lv/pazinojums-par-biedribam-nodibinajumiem-un-arstniecibas-iestadem-sniegto-materialo-vai-cita-veida-atbalstu-0

Disclosure of Value Transfers

Value category: "Meetings, educational support and site visits of HCPs"	<p>The company discloses value transfers in this category as per Option 2 of the MfE Transparency Requirements:</p> <p>Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows:</p> <ul style="list-style-type: none"> • Sponsorship for attending a third party organised congress (as per section 6.1): <ul style="list-style-type: none"> - name of congress, - aggregated amount spent for the congress, including the - number of Healthcare Professionals financially supported to attend • Site visits (as per section 6.3): aggregated amount spent, including the number of Healthcare Professionals financially supported to attend. • Company organised meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
Other Remarks	<p>For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained.</p> <p>Fees paid in connection with research & development activities or market research have not been disclosed.</p>
